With incentives to find new antibiotics signed into U.S. law last month, “multiple players are vying for the lead in the [multi-drug resistant tuberculosis (MDR-TB)] drug development niche,” Nature Medicine reports. “The fifth reauthorization of the U.S. Prescription Drug User Fee Act (PDUFA), signed into law on 9 July, includes a subsection called the Generating Antibiotic Incentives Now (GAIN) Act that aims to spur development of antibiotics for drug-resistant bacteria, including MDR-TB,” the news service writes, noting, “Drug makers that ask for approval of medicines to treat these pathogens will receive priority review, as well as five additional years of market exclusivity and fast-track status.” Currently, MDR-TB treatment “involves a bevy of regular tuberculosis medicines that, in many cases, must be administered for as long as two years or more … [and] don’t always work,” Nature Medicine states, adding, “The hope is that new medicines will shorten treatment times and improve cure rates.” The article discusses several medicines that are in different phases of research (Willyard, 8/6).
Study Finds 'Inconclusive' Evidence To Support Use Of WHO-Backed Drug To Prevent Hemorrhage During Labor
According to a study published Monday in the Journal of the Royal Society of Medicine, “[t]he World Health Organization [WHO] should review its approval of a drug used to prevent life-threatening bleeding in women in childbirth because there is not enough evidence that it is effective,” Reuters reports. The study finds that “the evidence to support the use of misoprostol is ‘at best inconclusive,’ yet it is increasingly used in poorer countries to prevent postpartum hemorrhage (PPH),” the news service writes, noting “researchers analyzed 172 previous studies on the use of misoprostol during labor and found that only six had enough information to say whether or not the drug was effective in preventing PPH in rural and community settings in poor countries” (Kelland, 8/20).
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia. “The return of the conference to the U.S. after 22 years, [was not only] a focus for celebration, but also provided a platform for vocal objection to the ban on injecting drug users and sex workers from entering the U.S.,” the editorial states, adding that “the absence of these groups from the meeting is rightly seen by many as a hindrance to developing approaches to combat the epidemic in regions where the disease is concentrated in these populations.”
In this post in the Results for Development Institute’s “Center for Global Health R&D Policy Assessment” blog, Hassan Masum, a consultant at the institute, interviews Alph Bingham, co-founder of Innocentive, an online platform for crowdsourcing technical solutions, about issues surrounding collaborative research and development (R&D) to advance health technologies. According to the blog, the interview is part of a series examining “how collaborative R&D can advance health technologies, and how its success can be gauged” (8/23).
Noting “Mitt Romney will become the official nominee for the Republican Party at its convention in Florida” this week, Kim Lufkin, communications officer for the Global Health Technologies Coalition, writes in this post in the coalition’s “Breakthroughs” blog, “Science and research will likely not appear on the agenda, as Romney, expected Vice Presidential candidate Paul Ryan, and others will instead focus on topics like reducing federal spending.” She continues, “It’s unfortunate that research will not be a part of the conversation, as new predictions coming out this week indicate that if Romney and Ryan win the election in November, changes could be coming for health research and efforts to develop much-needed new tools for global health.” She concludes, “It’s important that the candidates — from Obama and Vice President Biden to Romney and Ryan — start talking about these issues head-on,” and “no matter which party takes the White House in November, support for global health [research and development (R&D)] must continue” (8/24).
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday “to champion innovative solutions to the world’s major health problems,” Imperial College London reports in an article, which notes the summit, “the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development” and “will tackle maternal health, primary care, non-infectious diseases and aging societies” (8/1). “This is a unique summit. We’re gathering the global thought leaders, very much to exchange ideas, to learn from each other, when it comes to innovative solutions to the significantly great challenges facing health care systems globally,” summit chair Ara Darzi of the Institute for Global Health Innovation tells BBC Radio correspondent Claudia Hammond in a “Health Check” audio report (8/1).
Using a rodent model to examine the long-term effects of a potential malaria vaccine, a new study published in PLoS Biology by researchers at Penn State University shows that the vaccine could lead to the development of more virulent forms of malaria, the PLoS blog “Biologue” reports (Gross, 7/31). “Vicki Barclay, the study’s lead author, said it shows a need to track the long-term impact of any malaria vaccine, especially since any such vaccine is expected to be ‘leaky’ — meaning it won’t offer complete protection, and the disease will continue to spread, albeit at a slower rate,” CNN’s “The Chart” writes. “Researchers working with the leading candidate vaccine immediately questioned [the study], saying they’ve seen no sign of dangerous changes as a result of their work,” the blog continues (Hellerman, 8/1).
PEPFAR on Wednesday “announced awards for a $60 million initiative, with potential for additional funding in year three, to support implementation science research and the evaluation of programs established under PEPFAR,” according to a U.S. State Department media note. “These evaluations, funded through collaboration with the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the U.S. Agency for International Development (USAID), will contribute to the evidence base for HIV programs and maximize the impact of its investments in programs around the world. Data gathered will help partner countries to strengthen their efforts to prevent new HIV infections and save lives,” the media note states, adding, “More than 35 evaluations in over 12 countries will be funded in 2012” (8/1).
The Financial Times on Wednesday published a special report (.pdf) on global health policy to coincide with the Global Health Policy Summit in London. The special report features 10 articles on a variety of topics, including an article examining the complexities of applying health policies, delivering treatment and measuring program performances on a global level; an article highlighting potential strategies for lowering health care costs globally; and an article discussing the need for innovative approaches to combating infectious diseases (8/1).
“When you’re dealing with a global public health crisis, having an international presence isn’t just advisable — it is imperative,” Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), writes in this post in USAID’s “Impact” blog, adding, “That’s why [IAVI], in partnership with USAID, has worked diligently over the past several years to establish itself as a truly global non-profit partner.” She continues, “IAVI has created an enviable network of research centers in sub-Saharan Africa dedicated to assessing novel AIDS vaccine candidates in clinical trials and conducting supporting epidemiological studies on HIV,” and writes that these “partnerships have made meaningful contributions to the research capacity of many developing countries — a capability that is now helping local researchers tackle other diseases” (8/13).